Antibody Engineering Xchange EAST COAST 2018
Antibody Engineering
- What should be the most important selection criteria?
- Deciding factors to weigh risk and value
- Technology evolution, why and how?
- What does the trajectory predict for the future?
Senior Director & Head
Antibody Discovery
Sanofi
- What are the biggest challenges to overcome to enable selection of antibodies specific for multi-pass membrane proteins?
- What are the available technical solutions to these challenges?
- How can recombinant virus display and VLPs be used to overcome these challenges?
Senior Vice President
Research & Chief Scientific Officer
Vaccinex
- How do we know the selected antibodies bind a specific conformation such as a disease-specific form?
- How can we differentiate normal and disease-related forms?
- What methods can be used to validate protein conformations?
Professor
Chemical Engineering
Arizona State University
- Applications of protein sequencing- is DNA sequencing the only choice?
- Issues in antibody reproducibility and solutions. Is your mAb truly monoclonal?
- Advances in MS sequencing; does Ile/Leu differentiation matter?
- Future directions: MS sequencing in recombinant polyclonal antibodies.
Manager
Sales & Business Development
Rapid Novor
- Can NGS help your Ab discovery effort?
- NGS platform: MiSeq or HiSeq, which one is more suitable for Ab library sequencing?
- Sequencing Data analysis
- How to pick Ab hits from NGS sequencing results?
Senior Director
Henlix
Antibody Engineering
- Approaches to antigen affinity optimization – structure-based rational design vs high throughput screening vs phage display
- Optimization of effector function and multi-specificity subsequent or in parallel to affinity maturation
- When and how to assess developability potential of lead candidates
Vice President
Head of Discovery Therapeutics
Shire
- How early do we begin our developability assessments during the drug discovery process?
- How do we prioritise antibody attributes at each stage of the process?
- Which analytical approaches are most valuable in initial developability assessments?
Senior Scientist & Team Leader
Antibody Purification and Analytics
Fusion Antibodies
- How low is low enough for antibody’s effector function when a silent Fc format is needed?
- What are the benefits of engineering for antibody that specifically binds to one type of FcγR?
- What other factors contribute to antibody PK beside FcRn binding?
- What are the major issues of the existing Fc formats?
Senior Director, Head of Protein Engineering
Sanofi Genzymex
- How to choose an appropriate antibody modality? Bispecific, ADC, CAR-T, fragment, monotherapy, combinations
- The relevance/translation of animal models, transgenics, surrogates
- How to choose and evaluate antibody subclass?
Chief Scientific Officer
Carterra
- Approaches to personalized antibody product
- Translating from animal models to practical impacts in patients
- Challenges of in-vivo antibodies half-life in different areas of the body, e.g., brain
- Overcoming anti-drug antibodies
Senior Scientist, Translational Medicine
Aevi Genomic Medicine
Bispecific Antibodies
- Current limitations of bispecifics for the treatment of solid tumor indications
- Strategies to overcome current limitations of bispecifics for solid tumor targeting
President & Chief Scientific Officer
Maverick Therapeutics
- Duration of function
- Location, location, location
- Anti-drug antibodies
Chief, Molecular Structure Section
LVD, NIAID
National Institutes of Health
- Optimal building blocks for bispecific engineering
- Impact of bispecific formats on pharmacological activities
- Impact of bispecific formats on developability
Executive Director
Biologics Discovery
Merck
Antibody Drug Conjugates
- Engineering homogeneous and stable ADCs – are we there yet to address the therapeutic Index of ADC?
- How to address the on-target toxicities associated with ADCs?
- How to address the off-target toxicities often observed in ADCs?
- How to optimize the linker and warhead for preferred killing of tumor cells?
Senior Director & Fellow
R&D
MedImmune
- Site specific conjugation chemistries?
- Payloads and attachment chemistry?
- Linkers?
Vice President Discovery Biology & Pharmacology & Site Head
AMRI
- How can we use data from the clinical studies to improve the preclinical development of ADCs?
- How has ADC technology improved and what are the shortcomings?
- Will improvements in the preclinical development of ADCs improve the clinical success rates for ADCs?
- Does the unique structure and function of antibody-drug conjugates (ADCs) suggest specific mechanisms of primary resistance?
- How might some of the ADC components be modified to overcome these mechanisms of resistance?
Principal
Pharminteg LLC
- How do we design & interpret preclinical studies to be predictive of the clinic?
- How can we be more efficient: which assays matter, and which don’t?
- Which technologies are most promising for next-generation ADCs?
- Where is the greatest clinical opportunity for ADCs?
Senior Director
Head of Biology
Mersana Therapeutics
Cancer Immunotherapies
- What is needed to make informed choices about target selection?
- Platform modalities: does one size fit all?
- Limits of biology: biophysical properties of a drug vs target expression
- Is it all about T cells?
Global Head
NBE Drug Disposition
EMD Serono
- How to overcome the limitations for the identification of novel targets
- Have the most relevant I/O targets already been exploited, which one will be the next frontier?
- Impact of Ab format on MOA and efficacy
- Will the future be dominated by single agents or combinations?
Senior Director
Antibody Biotherapeutics,
Incyte Corporation
3:15pm – 4:15pm
- Rabbit monoclonal antibodies as an antibody tool for therapeutic antibody discovery
- Which technique is better: B cell cloning or phage display?
- How to achieve high reproducibility of antibodies?
Principal Scientist, Rabbit Monoclonal Antibody Discovery
ABclonal
4:20pm – 5:20pm
- Why a bispecific versus a combination of two antibodies?
- What valency of binding to each target is optimal for the desired mechanism of action?
- How do you select the optimal antibody specificities to function in context of a bispecific?
Vice President
Research
MacroGenics